TLDR
- First-quarter adjusted EPS reached $0.75, surpassing the $0.72 consensus forecast
- Quarterly revenue totaled $13.8 billion, bolstered by robust Eliquis demand
- Net income declined 9% annually to $2.7 billion; diluted EPS fell 10%
- 2026 annual outlook confirmed: adjusted EPS of $2.80–$3.00, revenue of $59.5B–$62.5B
- Shares climbed approximately 0.5% in premarket activity to roughly $26.33
Pfizer launched 2026 on a positive note with first-quarter results that topped expectations, pushing shares up about 0.5% to $26.33 in premarket activity.
The pharmaceutical giant delivered adjusted profit of $0.75 per share, exceeding the Street’s $0.72 projection. Quarterly revenue reached $13.8 billion.
The company’s anticoagulant Eliquis, among its top-selling medications, maintained its strong performance. This treatment continues serving as a critical revenue pillar while legacy products demonstrate resilience.
Chief Financial Officer David Denton highlighted 22% operational revenue expansion from newly introduced and acquired therapies. Sustaining this growth trajectory will be essential for the company’s strategy.
Net profit, meanwhile, experienced a downturn. The pharmaceutical company recorded $2.7 billion in net income, representing a 9% year-over-year decrease. Diluted earnings per share settled at $0.47, marking a 10% annual drop.
Annual Projections Remain Intact
Pfizer maintained its 2026 financial targets, keeping the outlook originally provided in December unchanged. Management continues to anticipate adjusted EPS between $2.80 and $3.00, with annual revenue projected at $59.5 billion to $62.5 billion.
Wall Street analysts had penciled in $2.96 per share and $61.4 billion in revenue, both figures falling within the company’s guidance parameters.
The pharmaceutical firm also reiterated that share repurchases will not occur in 2026. This stance remains firm irrespective of business performance throughout the year.
Chief Executive Albert Bourla expressed optimism. “We’re off to a strong start in 2026,” he stated, highlighting favorable Phase 3 trial results and promising mid-stage data.
Bourla emphasized oncology and obesity as two therapeutic areas where he expects Pfizer to “positioned to lead.”
Looming Patent Expirations Present Challenge
Approaching patent expirations represent one of Pfizer’s most significant near-term headwinds. Intellectual property protections on major revenue-generating drugs, including Eliquis, face expiration within the current decade.
The company has implemented strategies to mitigate this impact. Management has negotiated arrangements with generic drug makers to prolong exclusivity periods on select treatments, including Vyndaqel.
Additionally, the organization has been expanding its portfolio through strategic acquisitions and internal research to strengthen the development pipeline.
The research and development portfolio is reportedly progressing across numerous therapeutic areas, with oncology and obesity programs receiving heightened focus from executive leadership.
First-quarter revenue increased 5% year-over-year to $14.5 billion on a reported basis, outpacing market forecasts prior to the announcement.
The simultaneous beat on both profit and revenue metrics delivered a more solid quarter than investors had anticipated.
